Nexsen secures $1.2m grant for diagnostic expansion. The biotechnology company's Hong Kong subsidiary has received government funding to advance StrepSure, a rapid point-of-care diagnostic for Group B streptococcus in maternal health. The grant will support clinical validation through Hong Kong's hospital network and establish local manufacturing capabilities for Asia-Pacific markets. StrepSure addresses a critical gap in maternal healthcare by enabling faster identification of GBS colonisation during labour, potentially reducing serious neonatal complications. Hong Kong has been identified as a priority manufacturing and distribution hub due to its strong clinical infrastructure and efficient regulatory pathways for diagnostics.
Post from MarketNews_en
Log in to interact with content.